Camp4 Therapeutics entered into an amendment to its Securities Purchase Agreement to complete a second closing of its private placement. On Aug 3, 2026, the company sold 10.76 million common shares at $1.53 and pre-funded warrants for 21.93 million shares at $1.5299, plus 39,306 shares to management at $1.65, for gross proceeds of approximately $50.1 million. The pre-funded warrants carry a $0.0001 exercise price, are exercisable immediately on a cashless basis, and are subject to a 19.99% beneficial ownership cap. The financing follows milestone clearance to initiate the CMP-002 Phase 1/2 trial in Australia.
Agreement details:
- Agreement type: Amendment to Securities Purchase Agreement for private placement of common stock and pre-funded warrants
- Counterparty: Certain accredited investors
- Signed / Effective: Aug 03 2026 / Aug 03 2026
- Duration / Termination: At will
- Reason: Advance CMP-002 trial and strengthen liquidity
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.